Edition:
India

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

312.56USD
24 May 2019
Change (% chg)

$-2.70 (-0.86%)
Prev Close
$315.26
Open
$316.66
Day's High
$318.79
Day's Low
$308.51
Volume
144,019
Avg. Vol
276,562
52-wk High
$442.00
52-wk Low
$291.79

Latest Key Developments (Source: Significant Developments)

Regeneron Announces Updated Libtayo Results In Advanced Cutaneous Squamous Cell Carcinoma
Thursday, 16 May 2019 

May 16 (Reuters) - Regeneron Pharmaceuticals Inc ::UPDATED LIBTAYO® (CEMIPLIMAB-RWLC) RESULTS REINFORCE DURABLE AND SUBSTANTIAL RESPONSE RATES IN ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA.REGENERON PHARMACEUTICALS INC - NEW DATA AT ASCO INCLUDE MORE THAN DOUBLE PATIENTS PREVIOUSLY REPORTED.REGENERON PHARMACEUTICALS INC - MEDIAN OVERALL SURVIVAL STILL NOT REACHED WITH A MEDIAN FOLLOW-UP OF UP TO 17 MONTHS IN STUDY.  Full Article

Regeneron Pharmaceuticals Now Sees 2019 GAAP SG&A Between $1.695 Bln And $1.800 Bln
Wednesday, 8 May 2019 

May 7 (Reuters) - Regeneron Pharmaceuticals Inc ::REGENERON PHARMACEUTICALS INC - CORRECTS 2019 GAAP SG&A GUIDANCE; NOW SEES 2019 GAAP SG&A $1.695 BILLION–$1.800 BILLION - SEC FILING.REGENERON PHARMACEUTICALS - CORRECTS 2019 GAAP UNREIMBURSED RESEARCH AND DEVELOPMENT GUIDANCE; NOW SEES 2019 GAAP UNREIMBURSED RESEARCH AND DEVELOPMENT $2.280 BILLION – $2.400 BILLION.REGENERON PHARMACEUTICALS - PREVIOUS 2019 GAAP SG&A GUIDANCE WAS $1.695 BILLION–$1.800 BILLION.REGENERON PHARMACEUTICALS - PREVIOUS 2019 GAAP UNREIMBURSED RESEARCH AND DEVELOPMENT GUIDANCE WAS $1.855 BILLION–$2.000 BILLION.  Full Article

Regeneron Says FDA Approves Praluent To Prevent Heart Attack, Stroke And Unstable Angina Requiring Hospitalization
Saturday, 27 Apr 2019 

April 26 (Reuters) - Regeneron Pharmaceuticals Inc ::FDA APPROVES PRALUENT® (ALIROCUMAB) TO PREVENT HEART ATTACK, STROKE AND UNSTABLE ANGINA REQUIRING HOSPITALIZATION.REGENERON PHARMACEUTICALS INC SAYS FDA ALSO APPROVED PRALUENT AS AN ADJUNCT TO DIET, ALONE OR IN COMBINATION WITH OTHER LIPID-LOWERING THERAPIES.  Full Article

Regeneron Pharmaceuticals Inc Says CEO Leonard Schleifer's FY 2018 Total Compensation Was $26.5 Mln Vs $26.5 Mln In FY 2017
Saturday, 27 Apr 2019 

April 26 (Reuters) - Regeneron Pharmaceuticals Inc ::REGENERON PHARMACEUTICALS INC SAYS CEO LEONARD SCHLEIFER'S FY 2018 TOTAL COMPENSATION WAS $26.5 MILLION VERSUS $26.5 MILLION IN FY 2017 - SEC FILING.REGENERON PHARMACEUTICALS INC SAYS CHIEF SCIENTIFIC OFFICER GEORGE YANCOPOULOS' FY 2018 TOTAL COMPENSATION WAS $25.4 MILLION VERSUS $25.3 MILLION IN FY 2017.REGENERON PHARMACEUTICALS INC SAYS CFO ROBERT LANDRY'S FY 2018 TOTAL COMPENSATION WAS $9.4 MILLION.REGENERON PHARMACEUTICALS SAYS RATIO OF 2018 ANNUAL TOTAL COMPENSATION OF CEO TO MEDIAN OF ANNUAL TOTAL COMPENSATION OF EMPLOYEES WAS ABOUT 198 TO 1.  Full Article

Regeneron Says CHMP Issues Positive Opinion For Libtayo In Advanced Cutaneous Squamous Cell Carcinoma
Friday, 26 Apr 2019 

April 26 (Reuters) - Regeneron Pharmaceuticals Inc ::CHMP ISSUES POSITIVE OPINION FOR LIBTAYO® (CEMIPLIMAB) IN ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA.REGENERON PHARMACEUTICALS INC - EUROPEAN COMMISSION IS EXPECTED TO MAKE A FINAL DECISION ON APPLICATION FOR LIBTAYO IN COMING MONTHS.REGENERON PHARMACEUTICALS INC - CHMP OPINION IS BASED ON DATA FROM PIVOTAL, OPEN-LABEL, MULTI-CENTER, NON-RANDOMIZED PHASE 2 EMPOWER-CSCC-1 TRIAL.REGENERON PHARMACEUTICALS INC - AS PART OF CONDITIONAL APPROVAL, REGENERON AND SANOFI WILL NEED TO PROVIDE ADDITIONAL DATA FROM EMPOWER-CSCC-1.CHMP ISSUES POSITIVE OPINION FOR LIBTAYO® (CEMIPLIMAB) IN ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA.  Full Article

U.S., EU Patent Office Invalidates Amgen Subsidiary's Patents Claiming Antibodies To IL-4 Receptor
Saturday, 16 Feb 2019 

Feb 15 (Reuters) - Regeneron Pharmaceuticals Inc ::U.S. AND EU PATENT OFFICE DECISIONS INVALIDATE AMGEN SUBSIDIARY IMMUNEX'S PATENTS CLAIMING ANTIBODIES TO THE IL-4 RECEPTOR.REGENERON PHARMACEUTICALS INC - PATENT OFFICE DECISIONS ARE SUBJECT TO APPEAL BY IMMUNEX..  Full Article

Regeneron Reports Q4 Non-GAAP Earnings Per Share of $6.84, GAAP Earnings Per Share of $7.15
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - Regeneron Pharmaceuticals Inc ::REGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL AND OPERATING RESULTS.Q4 NON-GAAP EARNINGS PER SHARE $6.84.Q4 GAAP EARNINGS PER SHARE $7.15.Q4 EARNINGS PER SHARE ESTIMATE $5.60 -- REFINITIV IBES DATA.SEES 2019 CAPITAL EXPENDITURES $410 MILLION-$490 MILLION.Q4 2018 EYLEA (AFLIBERCEPT) INJECTION U.S. NET SALES INCREASED 11% TO $1.08 BILLION.QTRLY TOTAL REVENUES $1,928 MILLION VERSUS $1,582 MILLION.IN THE FOURTH QUARTER, GLOBAL NET SALES OF DUPIXENT RECORDED BY SANOFI WERE $318.8 MILLION, COMPARED TO $138.9 MILLION.Q4 GLOBAL NET SALES OF PRALUENT RECORDED BY SANOFI $93.2 MILLION VERSUS $63.3 MILLION YEAR AGO.REGENERON PHARMACEUTICALS - "IN 2019, WE PLAN TO STRENGTHEN EYLEA'S U.S. MARKET LEADERSHIP POSITION WITH A POTENTIAL APPROVAL IN DIABETIC RETINOPATHY".Q4 REVENUE VIEW $1.72 BILLION -- REFINITIV IBES DATA.REGENERON PHARMACEUTICALS - IN 2019 CO PLAN TO INITIATE TWO LYMPHOMA STUDIES WITH BISPECIFIC ANTIBODY, CD20XCD3.  Full Article

Sanofi announces positive CHMP regulatory feedback for Praluent
Monday, 4 Feb 2019 

Feb 4 (Reuters) - Sanofi SA ::* The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Praluent(®) (alirocumab), recommending a new indication as an adjunct to correction of other risk factors..* Praluent should be used in addition to a maximally tolerated dose of statin or can be used alone in patients intolerant to or inappropriate for statin therapy..* The CHMP opinion is based on data from ODYSSEY OUTCOMES, a Phase 3 cardiovascular outcomes trial that assessed the effect of Praluent in 18,924 patients who had an ACS between 1-12 months (median 2.6 months) before enrolling in the trial..  Full Article

Regeneron Provides Update On Commercial And Pipeline Progress At J.P. Morgan Healthcare Conference
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Regeneron Pharmaceuticals Inc ::REGENERON PROVIDES UPDATE ON COMMERCIAL AND PIPELINE PROGRESS AT J.P. MORGAN HEALTHCARE CONFERENCE.REGENERON PHARMACEUTICALS INC - SEES 2019 SANOFI COLLABORATION REVENUE BETWEEN $510 MILLION - $560 MILLION.REGENERON PHARMACEUTICALS INC - SEES 2019 CAPITAL EXPENDITURES $410 MILLION - $490 MILLION.REGENERON PHARMACEUTICALS INC - SEES FY 2019 NON-GAAP UNREIMBURSED RESEARCH AND DEVELOPMENT $1,590 MILLION - $1,710 MILLION.REGENERON PHARMACEUTICALS - EYLEA ACHIEVED $4.07 BILLION IN 2018 U.S. NET SALES (BASED ON PRELIMINARY, UNAUDITED Q4 2018 U.S. NET SALES OF $1.07 BILLION).  Full Article

Regeneron Pharmaceuticals Files For Potential Mixed Shelf Offering, Size Not Disclosed
Wednesday, 14 Nov 2018 

Nov 13 (Reuters) - Regeneron Pharmaceuticals Inc ::REGENERON PHARMACEUTICALS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

FDA approves expanded label for Regeneron/Sanofi's cholesterol drug

The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.